Phase 2 MS Study of BMS-986368 in Spasticity
A Phase 2 study was designed to evaluate the efficacy and safety of the drug BMS-986368 for treating spasticity in multiple sclerosis patients. With 200 participants, the study was randomized and controlled; however, no results have been posted about its outcomes.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
Why it matters
This study addresses the important symptom of spasticity in multiple sclerosis, which can significantly affect quality of life. Understanding the drug's impact could lead to better management strategies.
What this does not prove
No data are available to assess the drug's efficacy. Planned enrolment and endpoints do not count as findings, meaning we cannot draw any conclusions from this study yet.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 200 · basis not reported
- Randomised
- Yes
- Controlled
- Yes
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (6)
study phase"officialTitle": "A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)",
sample sizePlanned enrolment and endpoints are not findings.
randomized"officialTitle": "A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)",
controlled"officialTitle": "A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)",
findingsNo results are posted.
limitationsPlanned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.